GliaPharm SA

New Breakthrough in #Alzheimer's Research !   A groundbreaking study on the crucial role of astrocytes in #Alzheimer’s has just been published in #Science. https://lnkd.in/eyPC7996   Highlights of this pivotal paper on ALZFORUM features a commentary by GliaPharm SA's scientific founder, Pierre Magistretti, who draws insightful connections to our own therapeutic approach. https://lnkd.in/eXJnBtre   This research provides yet more evidence that astrocyte dysfunction is a key driver of hypometabolism in #Alzheimer. Excitingly, restoring metabolic function rescued cognition in #Alzheimer's models.   A significant step forward for #Alzheimer’s research and future treatments! #GlialCells #Astrocytes #Healthcare #Neuroscience #Innovation #GliaPharm

GliaPharm SA, an EPFL spinoff biotech company, has received a BRAINS grant to support a four-year study on glial cell behavior in various #neurological #disorders. All the best to the entire team! #technology #epfl #startup #technologytransfer #Innovation #EPFL The TTO team Andrea Crottini Mauro Lattuada Adam swetloff Natalia Giovannini Ghislain Singla Lucia Pavan Alberto D. Eric Meurville Bea Arnold Thomas Bourgeau https://lnkd.in/eQgGZMEp

We are honored to be part of a new BRAINS grant will support a four-year study into the behavior of glial cells in various brain diseases.    The GLIODEM BRAINS project will see top Dutch glia biologists and neuroscientists partner with Swiss biotech company #GliaPharm to deliver new insights. The project aims to uncover the consequences of reactive gliosis on neuronal functioning using human in vitro models. This collaborative effort combines academic expertise and industry innovation to advance our understanding of brain diseases, potentially paving the way for innovative treatments targeting glia. Read the news on our website: https://lnkd.in/e59gD7JC Or on the website of our academic colleagues: https://lnkd.in/ezXa7sBP https://lnkd.in/eNwcfYtE

GliaPharm's work on the metabolism of glial cells, and astrocytes in particular, is highlighted by Christian Wolf, head of epilepsy discovery research at UCB. Understanding astrocyte metabolism is our driving force at GliaPharm, and we are very proud to participate in this research with UCB, which we hope will lead to the development of new treatments for epilepsy. This is a fantastic adventure for us. https://lnkd.in/eFk3rB-w #GliaPharm #UCB #GlialCells #Healthcare #Neuroscience #Innovation

We were honored to sponsor and participate in the recent GLUT1 Deficiency Summit in Dallas, Texas, organized by the incredible Glut1 Deficiency Foundation. Our scientific founder, Pierre Magistretti, joined engaging discussions on Therapy Development, where he showcased our innovative research on targeting #glialcells in the brain. Also representing GliaPharm SA was our Chief Medical Officer, Uwe Meya, who added his clinical expertise to this dynamic event. A huge thank you to the Glut1 Deficiency Foundation and the entire community for an inspiring event filled with insightful discussions. Together, we are making strides towards better understanding GLUT1 Deficiency and discovering innovative therapies. #GLUT1-DS #GliaPharm #GlialCells #Healthcare #Biotech #Neuroscience #Innovation

Malicious people are offering jobs using addresses and logo that are not GliaPharm corporate. Don't reply, they're fake.

Exciting news: An insightful article was featured today in 24 heures and Tribune de Genève, spotlighting the $4.2M investment from Alzheimer's Drug Discovery Foundation ADDF in GliaPharm SA that will support the development of our leading compound towards clinics (article in French). The piece underscores our innovative strategy to address #alzheimers disease by targeting brain metabolism through glial cells - a method that may complement existing approaches in the field. https://lnkd.in/ewDcqV2T https://lnkd.in/eXuStwxy #Alzheimers #Biotech #GliaPharm #ADDF #GlialCells #Healthcare #Neuroscience #Innovation

GliaPharm is presenting at the 7th Annual Neuroscience Innovation Forum during the J.P. Morgan Healthcare Conference week in San Francisco. Come and meet us!

GliaPharm is presenting at the 7th Annual Neuroscience Innovation Forum during the J.P. Morgan Healthcare Conference week in San Francisco. Come and meet us!

Exciting News in Alzheimer's Research! GliaPharm SA has just received a substantial $4.2M investment from the Alzheimer's Drug Discovery Foundation (ADDF) to advance its novel #alzheimers therapy. The Swiss biotech focuses on enhancing brain metabolism through glial cells to tackle Alzheimer's disease. GliaPharm’s lead compound offers a promising therapeutic avenue for addressing the critical issue of brain hypometabolism, a hallmark of Alzheimer's. This funding marks a significant milestone, accelerating GliaPharm's development towards clinical trials and potentially transforming Alzheimer's treatment. Stay tuned for more updates, as GliaPharm, with the ADDF's backing, strides forward in this crucial healthcare challenge. Find out more on www.gliapharm.com/news and www.gliapharm.com #Alzheimers #Biotech #GliaPharm #ADDF #Glialcells #Healthcare #Neuroscience #Innovation